US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

48.84

+0.40000.83%

Volume:85.43K

Turnover:4.18M

Market Cap:14.93B

PE:21.90

High:49.03

Open:48.70

Low:48.65

Close:48.44

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.31

T/O Rate:0.03%

Dividend:2.09

Dividend Rate:4.28%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.61

PE(LYR):19.81

Loading ...

Overview Company News Filings

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Press Release: Correcting and Replacing Emera Declares Quarterly Dividends

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar

MT Newswires Live

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168

Emera Keeps Quarterly Dividend at $0.7325 a Share, Payable Aug. 17 to Shareholders of Record on Aug. 3

MT Newswires Live

Press Release: Emera Declares Quarterly Dividends

EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial

MT Newswires Live

Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway

Top Analyst Reveals Why Citigroup is a Top Bank Stock Ahead of Earnings

Benzinga_recent_news

Ethereum Nears Pivotal Price as Wall Street Buying Spree Resumes

Benzinga_recent_news

Press Release: Emera Teleconference on August 7 to Discuss Q2 2026 Results

Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Simply Wall St.

Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases

Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/EMA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":48.84,"timestamp":1789583961145,"preClose":48.44,"halted":0,"volume":85427,"delay":0,"changeRate":0.008257638315441901,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Trading","change":0.4,"latestTime":"09-16 14:39:22 EDT","open":48.7,"high":49.03,"low":48.65,"amount":4176883.798276,"amplitude":0.007845,"askPrice":48.87,"askSize":6,"bidPrice":48.83,"bidSize":800,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":48.44,"dividendRate":0.043177,"postHourTrading":{"tag":"盘后","latestPrice":48.44,"preClose":48.44,"latestTime":"19:30 EDT","volume":54475,"amount":2639178.46202,"timestamp":1789515007084,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.30806,"impliedVol":0.4051,"impliedVolPercentile":0.9721},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.30806,"shares":305783111,"dividePrice":2.091914,"high":49.03,"amplitude":0.007845,"preClose":48.44,"low":48.65,"week52Low":45.77,"pbRate":"1.61","psRate":"2.33","week52High":55.49,"institutionHeld":0,"latestPrice":48.84,"committee":0.985112,"eps":2.229761,"divideRate":0.042832,"volume":85427,"delay":0,"ttmEps":2.229761,"open":48.7,"prevYearClose":49.24,"prevWeekClose":49.19,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.38,"twentyDayClose":51.46,"sixtyDayClose":51.84,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-15","current":21.908178,"percent":0.458204,"low":16.637027,"twenty":17.78321,"median":20.257815,"eighty":21.038918,"high":22.07626,"avg":19.827678,"sd":1.473791,"marketCap":15047332456.73},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33},{"date":"2026-09-15","current":20.136369,"twenty":17.78321,"median":20.257815,"eighty":21.038918,"marketCap":15047332456.73}],"updateTime":1789583962599},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651449622","title":"Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449622","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449622?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201400,"startTime":"0","endTime":"0","summary":"STAFFORD, Texas, July  16, 2026  (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the \"Company\"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328362/0/en/Greenwich-LifeSciences-Announces-European-Approval-for-Combining-Both-HLA-Populations-in-FLAMINGO-01.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","GLSI","BK4081","BK4139","EMA","DTH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651498775","title":"Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2651498775","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651498775?lang=en_us&edition=fundamental","pubTime":"2026-07-16 02:15","pubTimestamp":1784139300,"startTime":"0","endTime":"0","summary":"CHICAGO, July  15, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3328051/0/en/Cosmos-Health-Share-Buyback-Surpasses-4-5-Million-Shares-Continues-Open-Market-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4175","COSM","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651645435","title":"Press Release: Correcting and Replacing Emera Declares Quarterly Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2651645435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651645435?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:16","pubTimestamp":1784110560,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia----July 15, 2026--Series J First Preferred Share quarterly dividend in release dated July 13, 2026, should read: $0.39660 .The updated release readsEMERA DECLARES QUARTERLY DIVIDENDSOn July 13, 2026, the Board of Directors of Emera Inc.  declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows:1.  $0.7325 per common share;","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651057651","title":"Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2651057651","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651057651?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:45","pubTimestamp":1784029500,"startTime":"0","endTime":"0","summary":"Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326747/0/en/Hemab-Therapeutics-Presents-Clinical-and-Preclinical-Data-from-Sutacimig-in-Glanzmann-Thrombasthenia-and-Factor-VII-Deficiency-at-the-ISTH-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","BK4081","BK4139","BK4588","EMA","GT","BK4585","BK4119"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175771","title":"Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175771","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651175771?lang=en_us&edition=fundamental","pubTime":"2026-07-14 16:56","pubTimestamp":1784019385,"startTime":"0","endTime":"0","summary":"Celltrion  voluntarily terminated and withdrew its European Phase 3 clinical trial application for CT-P51, its biosimilar to cancer drug Keytruda, from the European Medicines Agency, according to a regulatory filing on Tuesday.The South Korean biopharmaceutical company said the withdrawal follows changes in the global regulatory environment for biosimilar clinical trials.The company has updated its clinical and regulatory strategy for Phase 3 trials in previously untreated metastatic non-squamous non-small cell lung cancer, reducing the number of patients recruited for the trial.The company will continue the Phase 3 study in participating countries outside the European Union, comparing the efficacy and safety of CT-P51 against the reference drug Keytruda.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK4081","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651146031","title":"Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2651146031","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651146031?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947600,"startTime":"0","endTime":"0","summary":"Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in mor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326228/0/en/Cadrenal-Therapeutics-Late-Breaking-Phase-2-Data-Demonstrate-Greater-Than-25-Reduction-in-Thrombotic-Events-in-HIT-for-First-in-Class-12-LOX-Inhibitor-CAD-1005-at-ISTH-2026-Congres.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4081","BK4007","BK4173","KD","IE00B19Z4B17.USD","BK4134","BK4139","IE00B7SZL793.SGD","EMA","IE0031619046.USD","HIT","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111259","title":"Niagen Bioscience receives exclusive U.S. RPD, EMA OMPD for NB4168","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111259?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:35","pubTimestamp":1783946107,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NAGE) announced that the U.S. Food & Drug Administration, FDA, granted Rare Pediatric Disease, RPD, Designation for its propriet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-receives-exclusive-u-s-rpd-ema-ompd-for-nb4168-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-receives-exclusive-u-s-rpd-ema-ompd-for-nb4168-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","LABU","BK4585","RPD","BK4121","BK4097","EMA","LU1878469433.USD","NAGE","BK4588","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651139541","title":"Emera Keeps Quarterly Dividend at $0.7325 a Share, Payable Aug. 17 to Shareholders of Record on Aug. 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2651139541","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651139541?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:29","pubTimestamp":1783938565,"startTime":"0","endTime":"0","summary":"Emera Keeps Quarterly Dividend at $0.7325 a Share, Payable Aug. 17 to Shareholders of Record on Aug. 3","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651188901","title":"Press Release: Emera Declares Quarterly Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2651188901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651188901?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:00","pubTimestamp":1783936800,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia----July 13, 2026--On July 13, 2026, the Board of Directors of Emera Inc.  declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after August 17, 2026 to the applicable shareholders of record at the close of business on August 3, 2026, as follows:1.  $0.7325 per common share;","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651193568","title":"EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651193568","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651193568?lang=en_us&edition=fundamental","pubTime":"2026-07-13 13:25","pubTimestamp":1783920304,"startTime":"0","endTime":"0","summary":"EirGenix  said the European Medicines Agency  approved a variation application submitted by its licensing partner Sandoz AG to add a 420 mg vial presentation for its trastuzumab biosimilar HERWENDA .The biosimilar is indicated for the treatment of HER2-positive early and metastatic breast cancer, as well as metastatic gastric cancer, according to a Sunday Taiwan Exchange filing.EirGenix said the approval follows the launch of the 150 mg presentation in Slovakia and supports preparations for a broader commercial rollout across the European Union.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","EMA","BK4081","BK7129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651625311","title":"Biotron Clears First SedRx Milestone After EMA Feedback on Regulatory Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2651625311","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651625311?lang=en_us&edition=fundamental","pubTime":"2026-07-13 09:32","pubTimestamp":1783906344,"startTime":"0","endTime":"0","summary":"Biotron ( ($AU:BIT) ) has shared an announcement. Biotron has met the first milestone under its Sedarex acquisition after securing formal feedback ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biotron-clears-first-sedrx-milestone-after-ema-feedback-on-regulatory-pathway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biotron-clears-first-sedrx-milestone-after-ema-feedback-on-regulatory-pathway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157254","title":"Top Analyst Reveals Why Citigroup is a Top Bank Stock Ahead of Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157254","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157254?lang=en_us&edition=fundamental","pubTime":"2026-07-12 10:04","pubTimestamp":1783821840,"startTime":"0","endTime":"0","summary":"Josh Brown, a top Wall Street analyst, has explained why Citigroup stock is his best banking group ahead of its earnings","market":"us","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/12/citigroup.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/12/citigroup.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/07/60404635/top-analyst-reveals-why-citigroup-is-a-top-bank-stock-ahead-of-earnings","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60404635/top-analyst-reveals-why-citigroup-is-a-top-bank-stock-ahead-of-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157853","title":"Ethereum Nears Pivotal Price as Wall Street Buying Spree Resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157853","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157853?lang=en_us&edition=fundamental","pubTime":"2026-07-12 03:56","pubTimestamp":1783799760,"startTime":"0","endTime":"0","summary":"Ethereum price is nearing a crucial resistance level as Wall Street restarts the buying spree, with ETF inflows continuing this week.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/11/Eth-Coin-With-Blurred-Candlestick-Chart-.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/07/11/Eth-Coin-With-Blurred-Candlestick-Chart-.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/crypto/26/07/60404460/ethereum-nears-pivotal-price-as-wall-street-buying-spree-resumes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/26/07/60404460/ethereum-nears-pivotal-price-as-wall-street-buying-spree-resumes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LFGY","BETH","QETH","MAXI","ARKY","09179","CBTJ","CBOJ","ETH.USD.CC","CBTY","FETH","ETU","SHAP.U","03179","03046","BEGS","ETQ","CETH","SETH","ETHA","DEFI","ETCO","ETHT","EZET","BTCL","BTF","ETHU","EMA","BKCH","09009","ETHW","BTCI","03009","ETHV","IBIT","ETH","09046","BITQ","EETH","ETH.USD.HKCC","ETHE","ETHI","ETHD","GDLC","STCE","BETE","BITW","AETH","YETH","CRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650518185","title":"Press Release: Emera Teleconference on August 7 to Discuss Q2 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2650518185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650518185?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:02","pubTimestamp":1783677720,"startTime":"0","endTime":"0","summary":"HALIFAX, Nova Scotia--(BUSINESS WIRE)--July 10, 2026--Today Emera (TSX/NYSE: EMA) announced that it will release its Q2 2026 results on Friday, August 7, 2026, before markets open. The Company will ho","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650971089","title":"Cosmos Health Expands Share Buyback to 4.14 Million Shares; Continues Open Market Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2650971089","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650971089?lang=en_us&edition=fundamental","pubTime":"2026-07-10 03:45","pubTimestamp":1783626300,"startTime":"0","endTime":"0","summary":"CHICAGO, July  09, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/09/3325172/0/en/Cosmos-Health-Expands-Share-Buyback-to-4-14-Million-Shares-Continues-Open-Market-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4175","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650919584","title":"Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2650919584","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650919584?lang=en_us&edition=fundamental","pubTime":"2026-07-09 05:07","pubTimestamp":1783544820,"startTime":"0","endTime":"0","summary":"BOSTON, July  08, 2026  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324480/0/en/Rhythm-Pharmaceuticals-Announces-The-New-England-Journal-of-Medicine-Publication-of-Phase-3-TRANSCEND-Trial-Results-in-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","EC","VUS","BMI","AVP","EMA","CHMP","BK4157","BK4081","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915671","title":"Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915671","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915671?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:40","pubTimestamp":1783539600,"startTime":"0","endTime":"0","summary":"CHICAGO, July  08, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3324405/0/en/Cosmos-Health-Share-Buyback-Surpasses-4-Million-Shares-Continues-Open-Market-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","COSM","BK4175","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649506939","title":"Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649506939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649506939?lang=en_us&edition=fundamental","pubTime":"2026-07-08 11:27","pubTimestamp":1783481228,"startTime":"0","endTime":"0","summary":"Zambon and Amneal Pharmaceuticals recently announced that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Hopledo, a modified-release levodopa/carbidopa therapy for European adults with Parkinson’s disease experiencing moderate to severe motor fluctuations despite existing oral regimens.\nThis regulatory milestone, underpinned by Phase 3 RISE-PD data and an exclusive European licensing deal, highlights Amneal’s...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/did-emas-positive-hopledo-ruling-just-shift-amneal-pharmaceu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/did-emas-positive-hopledo-ruling-just-shift-amneal-pharmaceu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","EMA","AMRX","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649934778","title":"Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2649934778","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649934778?lang=en_us&edition=fundamental","pubTime":"2026-07-08 02:27","pubTimestamp":1783448820,"startTime":"0","endTime":"0","summary":"CHICAGO, July  07, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (\"Cosmos Health\" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323580/0/en/Cosmos-Health-Share-Buyback-Expands-to-3-87-Million-Shares-Continues-Open-Market-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","BK4175","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649387309","title":"Cosmos Health Reports Preliminary Record Q2 and H1 2026 Revenue, Up Over 30% Year-Over-Year; Continues Open Market Share Repurchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2649387309","media":"GlobeNewswire","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649387309?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:29","pubTimestamp":1783430940,"startTime":"0","endTime":"0","summary":"Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323319/0/en/Cosmos-Health-Reports-Preliminary-Record-Q2-and-H1-2026-Revenue-Up-Over-30-Year-Over-Year-Continues-Open-Market-Share-Repurchases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COSM","EMA","BK4081","BK4175"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}